Literature DB >> 26303056

Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia.

Gulsum Ozet1, Mesude Falay2, Simten Dagdas2, Funda Ceran2.   

Abstract

BACKGROUND: In recent years, the clinical and biological features governing the clinical course of chronic lymphocytic leukemia (CLL) have been most extensively studied. Human leukocyte antigen-G (HLA-G) allows tumor cells to escape from the antitumor effect of the immune system. Recent studies have shown that various tumor cells show an increased HLA-G expression. Data regarding HLA-G expression in CLL are limited and controversial. The aim of this work is to evaluate flow cytometry study of HLA-G expression on cell surface and assess its relationship with other prognostic factors (CD38, ZAP70, beta 2 microglobulin [β2MG]) in patients with CLL. DESIGN AND METHODS: Forty-five newly diagnosed CLL cases. White blood cell count, lymphocyte absolute count, hemoglobin level, platelet count, serum lactate dehydrogenase activity, and serum β2MG level were studied at admission. In each patient, morphologic diagnosis of B-CLL was confirmed by flow cytometry HLA-G, CD38 and ZAP70 expression levels were measured with four-color flow cytometry.
RESULTS: HLA-G positivity ranged between 1% and 12% in CLL patients. A significant correlation was found with CD38, ZAP70, disease stage, and β2MG (P < 0.001). The off-treatment follow-up period was longer in the HLA-G negative group (P < 0.022).
CONCLUSIONS: In conclusion, we suggest that, in addition to other prognostic factors, surface HLA-G expression can be considered as an independent prognostic factor. However, our work should be confirmed by further prospective studies, a longer off-treatment follow-up period, and a standardized method.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic lymphocytic leukemia (CLL); human leukocyte antigen-G (HLA-G); prognostic factors

Mesh:

Substances:

Year:  2015        PMID: 26303056      PMCID: PMC6807200          DOI: 10.1002/jcla.21868

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia.

Authors:  S Mizuno; N Emi; M Kasai; A Ishitani; H Saito
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

3.  Progress of HLA-G in cancer.

Authors:  Edgardo D Carosella; Jean Dausset
Journal:  Semin Cancer Biol       Date:  2003-10       Impact factor: 15.707

Review 4.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 5.  Chronic lymphocytic leukemia: prognostic factors and impact on treatment.

Authors:  Terri L Parker; Matthew P Strout
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

6.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia.

Authors:  Mohamed A Attia; Nahla A Nosair; Amro Gawally; Gamal Elnagar; Eid M Elshafey
Journal:  Acta Haematol       Date:  2014-02-15       Impact factor: 2.195

8.  Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  K Giannopoulos; A Dmoszyńska; A Bojarska-Junak; M Schmitt; J Roliński
Journal:  Folia Histochem Cytobiol       Date:  2008       Impact factor: 1.698

Review 9.  HLA-G and MIC expression in tumors and their role in anti-tumor immunity.

Authors:  Barbara Seliger; Hinrich Abken; Soldano Ferrone
Journal:  Trends Immunol       Date:  2003-02       Impact factor: 16.687

10.  Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia.

Authors:  G Perez-Chacon; S Rosado; N Rebolleda; I Losada-Fernandez; J A Vargas; M Morado; J Jorda; P Perez-Aciego
Journal:  Int J Lab Hematol       Date:  2008-02-03       Impact factor: 2.877

View more
  2 in total

1.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 2.  The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.

Authors:  Simon Jasinski-Bergner; Markus Eckstein; Helge Taubert; Sven Wach; Christian Fiebig; Reiner Strick; Arndt Hartmann; Barbara Seliger
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.